The shadow of generic challenges has long loomed around copyright’s famous drug, Viagra, raising questions about the future of connected medicinal holdings. While early years saw impressive profits, the exclusivity lapse has created the way for less expensive alternatives, potentially diminishing profitability and presenting a genuine hazard for